EpiVax, Inc.

Class 042: Research and development of vaccines and medicines; Pharmaceutical research and development; Vaccine research and development

Scientific and technical services, namely, analysis and testing of protein therapeutic sequences in the field of immunogenicity | Health screening services in the field of immunogenicity; Providing medical information to scientists in the form of reports in the field of immunogenicity

Research, development, engineering and testing services in the fields of proteins and T cell vaccines; Providing temporary use of non- downloadable software to predict the immunogenicity of protein therapeutics, to deimmunize proteins and to design T cell vaccines

Scientific and technical services, namely, analysis and testing of protein therapeutic sequences in the field of immunogenicity

Scientific research consulting services in the field of bio-infomatics for the treatment of humans

Class 042: Medical research services in the field of cancer, namely, computational processing of cancer and normal protein sets; Class 044: Medical analysis services for the treatment of cancer, namely, analysis of cancer and normal protein sets

Computer software for processing cancer/normal protein sets, identifying high-quality specific neo-antigens, and designing personalized cancer vaccines; Medical testing and analysis of cancerous and normal protein sets for identifying high-quality patient specific neo-antigens for the purpose of diagnosis and treatment; Research, development, engineering and testing services in the field of personalized cancer vaccines; providing temporary use of non-downloadable software to predict the immunogenicity of protein therapeutics, to deimmunize proteins and to design T cell vaccines

Class 042: Research and development of personalized cancer vaccines; medical research in the field of cancer, namely, processing cancer and normal protein sets and identifying high-quality patient specific neo-antigens; Class 044: Medical analysis services for the treatment of cancer, namely, processing of cancer and normal protein sets and identifying high-quality patient specific neo-antigens